10-Q · May 13, 2026
Stereotaxis reported a disappointing Q1 2026, with revenue of $6.3 million, falling short of the estimated $8.62 million. The gross margin improved to 60%, but operating losses widened, leading to an EPS of -$0.06,…
Earnings analysis · 10-Q
STXS earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Stereotaxis reported Q2 2026 revenue of $7.670 million, diluted EPS of $(0.05), and a 58% gross margin; revenue and EPS missed consensus, while gross margin improved year over year from 52.0% to 58%. Robotic catheter…
Read full summary
Stereotaxis reported Q2 2026 revenue of $7.670 million, diluted EPS of $(0.05), and a 58% gross margin; revenue and EPS missed consensus, while gross margin improved year over year from 52.0% to 58%. Robotic catheter revenue exceeded $1 million, and management expects recurring revenue of approximately $7 million in Q3 and $8 million in Q4, plus $3 million of system revenue in each quarter. The outlook is constructive but execution and liquidity remain material risks because cash-flow profitability is not anticipated until the first half of 2027 and supplemental Robocath acquisition risks were added.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.05
- Gross margin
- 58.0%
What stood out
-
Revenue and EPS missed consensus
Q2 2026 revenue was $7.670 million, while diluted EPS was $(0.05). Revenue was approximately 10.6% below the $8.580 million consensus estimate and EPS missed the $(0.04) estimate.
-
Gross margin improved year over year
Gross margin was 58% in Q2 2026, up from 52.0% in Q2 2025 and down from 60.3% in Q1 2026, indicating year-over-year improvement but sequential compression.
-
Catheter adoption accelerated
Robotic catheter revenue exceeded $1 million in Q2 2026, signaling accelerating adoption of the company’s recurring-product offering.
-
Second-half revenue outlook provided
Management expects recurring revenue of approximately $7 million in Q3 2026 and $8 million in Q4 2026, with system revenue of approximately $3 million in each quarter.
-
Cash-flow breakeven targeted
Management anticipates cash-flow profitability in the first half of 2027, providing a timing marker for the company’s path toward reduced cash consumption.
-
Mixed operating trajectory
The quarter’s diluted EPS of $(0.05) was weaker than the $(0.04) consensus estimate and unchanged from Q2 2025, while management’s outlook points to sequential recurring-revenue growth from $7 million in Q3 to $8 million in Q4.
What to watch
-
Quarterly results missed estimates
Q2 2026 revenue of $7.670 million missed the $8.580 million consensus estimate by approximately 10.6%, and diluted EPS of $(0.05) missed the $(0.04) estimate.
-
Cash-flow breakeven remains distant
The company remains dependent on execution to reach cash-flow profitability in the first half of 2027; the filing and related outlook provide no nearer-term cash-flow profitability date.
-
Robocath integration risks added
The 10-Q states that there were no material changes to the risk factors in the December 31, 2025 Form 10-K, except for supplemental risks related to the Robocath acquisition incorporated from the July 15, 2026 Form 8-K.
Management's outlook
Management provided a second-half outlook of approximately $7 million recurring revenue and $3 million system revenue in Q3 2026, and approximately $8 million recurring revenue and $3 million system revenue in Q4 2026. Cash-flow profitability is anticipated in the first half of 2027; no comparable prior outlook was provided.
Earlier filings 4
10-K · March 12, 2026
Stereotaxis describes a strategy of expanding its Robotic Magnetic Navigation (RMN) franchise across electrophysiology and additional endovascular indications while commercializing new lab software (Synchrony / SynX)…
10-Q · May 13, 2025
Stereotaxis posted quarterly revenue of $7.47M, up 8.6% from $6.88M a year ago, driven by a $5.51M disposables/services cohort (+29.0% YoY) while systems revenue declined. Gross margin dollars increased modestly to…
10-K · March 14, 2025
Stereotaxis (STXS) describes a strategy of expanding its Robotic Magnetic Navigation (RMN) technology beyond electrophysiology into other endovascular indications, bolstered by the July 31, 2024 acquisition of Access…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.